Efficacy and safety at 12 months of PRESERFLO® combined with DuraGen® and morphological evaluation using…

Cohort studyArchivos de la Sociedad Espanola de Oftalmologia· Jul 2026

Efficacy and safety at 12 months of PRESERFLO® combined with DuraGen® and morphological evaluation using AS-OCT.

V T Pérez-Torregrosa, A Caro-Ortega, I Pérez-Cantó … A Duch-Samper

Read paper

GlaucomaCohort studyTreatmentQ3IF 0.8

PRESERFLO with DuraGen implantation lowered eye pressure by 47.9% at 12 months.

Efficacy and safety at 12 months of PRESERFLO® combined with DuraGen® and morphological evaluation using AS-OCT.

V T Pérez-Torregrosa … A Duch-Samper

Archivos de la Sociedad Espanola de Oftalmologia · Jul 2026 · Q3 in Ophthalmology

Background

To evaluate the efficacy and safety at 12 months of PRESERFLO® implantation combined with 0.04% MMC and the interposition of DuraGen® in patients with moderate or severe glaucoma, and to analyse bleb morphology using anterior segment optical coherence tomography (anterior segment optical coherence tomography).

Methods

Prospective study including 50 eyes that underwent PRESERFLO® implantation with 0.04% MMC and DuraGen®, either as a standalone procedure or combined with cataract surgery.

n = 50 eyes

Results

eye pressure dropped substantially, a sign of better glaucoma control

Preoperative IOP

26.8mmHg

Postoperative IOP

13.1mmHg

More results

Complete success was achieved in 42 eyes (84%), qualified success in 5 eyes (10%), and failure was observed in 3 eyes (6%).

The most frequent complication was choroidal detachment (22%).

No significant differences were observed between standalone and combined surgery regarding final IOP or surgical success rates.

More results

In successful cases, anterior segment optical coherence tomography more frequently showed a suprascleral aqueous lake, whereas failed cases presented a flat bleb.

“

Conclusion · 1 of 2

PRESERFLO® implantation combined with 0.04% MMC and DuraGen® was effective and safe for IOP control at 12 months.

Conclusion · 2 of 2

anterior segment optical coherence tomography allows identification of morphological patterns associated with success and failure.

Efficacy and safety at 12 months of PRESERFLO® combined with DuraGen® and morphological evaluation using AS-OCT.

Efficacy and safety at 12 months of PRESERFLO® combined with DuraGen® and morphological evaluation using AS-OCT.

Related papers